Can Secretome Therapeutics turn its expanded leadership team into a Duchenne breakthrough?

Secretome Therapeutics expanded its rare disease leadership team on July 27, 2026, appointing Teji Singh as chief medical officer, David Chapman as senior vice president of operations, Karin Lucas as vice president of medical affairs and Maggie Loeffler as vice president of finance and administration. The Plano, Texas-based biotechnology company also moved former chief medical officer Marshelle Smith into the role of chief development officer. The appointments follow Secretome Therapeutics’ $30 million Series A financing from RA Capital Management and are intended to support the planned advancement of STM-01 into later-stage studies for Duchenne muscular dystrophy-associated cardiomyopathy. The central question is whether Secretome Therapeutics is building an organisation ahead of an approaching clinical breakthrough or adding late-stage infrastructure before sufficient controlled evidence has emerged.

Secretome Therapeutics is privately held, meaning the leadership expansion does not create an immediate public-market reaction or share-price catalyst. It does, however, provide a useful signal about how management expects the company to evolve. Recruiting executives across clinical development, medical affairs, operations, finance, market access and product-launch disciplines suggests Secretome Therapeutics is preparing for a more complex phase in which scientific development must be accompanied by regulatory execution, manufacturing discipline, patient engagement and commercial planning.

Why is Secretome Therapeutics expanding its rare disease leadership team at this stage?

The timing reflects a transition from founder-led platform development toward institutional biotechnology execution. Secretome Therapeutics is no longer positioning STM-01 solely as an experimental cardiac cell therapy being evaluated in small early-stage studies. The company is increasingly presenting Duchenne muscular dystrophy-associated cardiomyopathy as the lead indication around which its clinical, regulatory and organisational strategy will be built.

Teji Singh brings more than three decades of clinical development and regulatory experience, including recent responsibility for clinical programmes at Sarepta Therapeutics and earlier cell and gene therapy roles at Sanofi and Genzyme. That background is particularly relevant because Duchenne muscular dystrophy development requires coordination across paediatric neuromuscular specialists, cardiologists, regulators, patient organisations and families dealing with a progressive disease. Secretome Therapeutics said Singh has helped advance therapies from early clinical development through regulatory approval, experience that could become increasingly important as STM-01 moves beyond exploratory studies.

The appointment also gives Secretome Therapeutics direct experience from one of the most prominent companies in the Duchenne market. Sarepta Therapeutics helped establish gene therapy and exon-skipping medicines as important treatment approaches, although the Duchenne regulatory environment has become more demanding following safety concerns and changes to the authorised use of Elevidys. The United States Food and Drug Administration added a boxed warning and limited Elevidys to ambulatory patients aged four years and older in November 2025 following reports of fatal liver injury among non-ambulatory patients. That background illustrates why regulatory judgement and safety planning are not supporting functions in Duchenne development. They are central strategic capabilities.

How do the new appointments change Secretome Therapeutics’ ability to execute STM-01 trials?

The leadership expansion covers several capabilities that normally become more important as a biotechnology company approaches larger, more expensive and more operationally demanding studies. Singh can provide clinical and regulatory leadership, while Smith’s move to chief development officer preserves continuity across the broader regenerative medicine pipeline. Secretome Therapeutics said Smith will lead pipeline development in cardioimmunology after overseeing the first-in-human STM-01 programme as chief medical officer.

David Chapman’s appointment as senior vice president of operations is equally revealing. His experience includes commercial strategy, market access, organisational development and more than 20 product launches across rare diseases and other specialty markets. Companies do not need a complete commercial organisation during early clinical development, but they do need to understand how an investigational therapy could be manufactured, distributed, reimbursed and integrated into specialist care if pivotal evidence proves supportive.

That issue is particularly important for a repeatedly administered, allogeneic cell therapy. Secretome Therapeutics must eventually demonstrate not only that STM-01 produces a meaningful clinical effect, but also that it can be manufactured consistently, transported reliably and administered without creating an impractical burden for patients, hospitals or payers. The company’s proposed THRIVE 2 model includes home dosing, no required washout from existing treatment, no upper age restriction and eligibility for ambulatory and non-ambulatory participants. Those features could widen access, although their operational feasibility and regulatory acceptability will need to be demonstrated through the programme.

Karin Lucas adds medical affairs and Duchenne community experience, including previous work at Sarepta Therapeutics, Biogen Idec and Cardinal Health. Medical affairs becomes increasingly important when a therapy addresses an area in which clinical endpoints, patient selection and the relationship between cardiac and skeletal-muscle outcomes may require careful explanation. Engagement with clinicians, researchers and advocacy organisations can also help a company understand whether its trial design captures outcomes that matter to patients and treating physicians.

Maggie Loeffler’s appointment adds financial reporting, capital-raising and public-company transaction experience. Her background includes an initial public offering, a reverse merger and United States Securities and Exchange Commission reporting. That does not mean Secretome Therapeutics is preparing for an imminent listing, but it gives the company greater capacity to manage institutional financing, corporate controls and the growing administrative demands associated with late-stage development.

What does the RA Capital financing allow Secretome Therapeutics to build around STM-01?

Secretome Therapeutics closed a $30 million Series A financing from RA Capital Management in May 2026, with RA Capital serving as the sole investor. The company said the proceeds would support operations and advance STM-01 toward Phase 2 and Phase 3 development in Duchenne muscular dystrophy-associated cardiomyopathy and other cardiomyopathies linked to neuromuscular disease.

The Series A followed a $20.4 million financing announced in November 2024, taking disclosed capital from those two rounds to at least $50.4 million. The earlier round was intended to support initial clinical studies, manufacturing scale-up and preclinical pipeline development, while the RA Capital investment appears more closely associated with the company’s shift toward rare disease and late-stage execution. The distinction matters because the cost structure of a biotechnology company can change rapidly once it adds larger trials, specialised personnel, manufacturing commitments and regulatory programmes.

The expanded leadership team therefore represents both increased capability and a higher operating commitment. Experienced executives can improve trial design, regulatory interactions and organisational discipline, but they also raise the company’s fixed-cost base before commercial revenue exists. Secretome Therapeutics will need to deploy its capital selectively and avoid building a full commercial structure before the clinical programme justifies it.

RA Capital’s participation provides external validation of the development strategy, but financing is not clinical validation. The investment gives Secretome Therapeutics more time and greater organisational capacity to test STM-01. It does not determine whether the product will meet efficacy, safety or regulatory requirements.

Why does Duchenne cardiomyopathy create a distinct opportunity for STM-01?

Duchenne muscular dystrophy is caused by mutations that prevent normal production of dystrophin, leading to progressive skeletal-muscle weakness as well as deterioration of cardiac and respiratory function. Recent treatments have expanded options through corticosteroids, exon-skipping medicines, nonsteroidal therapy and gene therapy, but the population remains medically heterogeneous and cardiac disease continues to be a major source of morbidity and mortality.

Secretome Therapeutics is attempting to differentiate STM-01 by targeting inflammatory and fibrotic pathways involved in declining myocardial function. The product consists of neonatal cardiac progenitor or cardiac-derived cells that the company believes can support immunomodulation, reduce fibrosis and promote tissue repair through bioactive factors released by the cells. These mechanisms have been observed primarily in preclinical cardiac injury models and must still translate into reproducible clinical benefit.

This creates a potentially complementary rather than directly substitutive positioning. A patient could theoretically receive therapies aimed at dystrophin production, skeletal-muscle preservation or inflammation while also receiving a cardiac-directed treatment. Secretome Therapeutics’ proposed study design, which does not require patients to stop existing therapies, appears intended to test STM-01 within that evolving standard-of-care environment.

The strategic opportunity is therefore not simply to compete for the entire Duchenne market. It is to establish STM-01 as a broadly applicable cardiac therapy that could be used across mutations, ages, ambulation status and prior treatment histories. Achieving that position would require strong evidence that the therapy improves or preserves cardiac function beyond what patients receive from established medical management.

How does STM-01 compare with the emerging cell therapy competition in Duchenne cardiomyopathy?

The most important competitive reference is Capricor Therapeutics’ deramiocel, an investigational human allogeneic cardiosphere-derived cell therapy. The United States Food and Drug Administration scheduled an advisory committee meeting for July 29, 2026, to examine Capricor’s Biologics License Application for deramiocel in Duchenne muscular dystrophy cardiomyopathy. The application has an August 22, 2026, target action date.

Secretome Therapeutics announced its leadership appointments two days before that meeting, although there is no evidence that the timing was directly connected. The proximity is nevertheless strategically relevant because the regulatory discussion surrounding deramiocel may shape expectations for clinical endpoints, cardiac measurements, manufacturing controls and evidence standards across the wider Duchenne cell therapy field.

Deramiocel and STM-01 should not be treated as interchangeable products. Deramiocel is based on cardiosphere-derived cells, while STM-01 is derived from neonatal cardiac progenitor or cardiac-derived cell biology. Capricor also has a much more advanced clinical evidence package, including randomised Phase 2 research and a Phase 3 programme supporting its regulatory submission.

The deramiocel programme could affect Secretome Therapeutics in two directions. A favourable regulatory outcome could validate DMD cardiomyopathy as a commercially and clinically recognisable treatment category, making physicians, investors and regulators more familiar with repeated allogeneic cell therapy. Conversely, approval of an established competitor could raise the evidence threshold for STM-01 and make differentiation on efficacy, safety, convenience or manufacturing essential.

What clinical evidence must STM-01 produce before the leadership buildout is validated?

STM-01 remains an investigational therapy, and the publicly available evidence is still substantially earlier than the company’s organisational expansion may initially suggest. Secretome Therapeutics began a Phase 1 study in heart failure with preserved ejection fraction in March 2025. The registered open-label study was designed to enrol up to 12 participants across two ascending-dose cohorts receiving 100 million or 200 million cells.

The company also initiated a Phase 1 programme in dilated cardiomyopathy in October 2025, while its website now identifies Duchenne muscular dystrophy-associated cardiomyopathy as the lead indication. The proposed THRIVE 2 study is described as an open-label evaluation of STM-01 in paediatric and adult patients, with cardiac monitoring that includes left ventricular ejection fraction.

Open-label studies can provide important information about safety, dosing, feasibility and biological activity, but they are vulnerable to selection effects, measurement variability and the natural fluctuation of disease. For STM-01 to support a pivotal programme and eventual regulatory filing, Secretome Therapeutics will need to establish an endpoint strategy capable of showing that any cardiac improvement or preservation is attributable to the therapy rather than background treatment or natural-history variation.

Durability will also matter. Duchenne muscular dystrophy is a lifelong progressive disease, meaning a temporary change in imaging or biomarkers may not be sufficient unless it translates into sustained cardiac function, reduced progression or another clinically meaningful outcome. Repeated dosing also requires a clear long-term safety profile, particularly around infusion reactions, immune responses and manufacturing consistency.

Could Secretome Therapeutics create additional value from the broader neonatal cell platform?

Secretome Therapeutics is developing STM-21, a preclinical cell-free programme based on components of the STM-01 secretome, including extracellular vesicles and exosomes. It is also working on STM-03, which the company describes as a next-generation engineered-cell programme for cardiac and other serious diseases.

A cell-free product could eventually offer advantages in manufacturing, storage or administration compared with a living-cell therapy, but STM-21 remains preclinical. Its value should therefore be considered platform optionality rather than an independently validated asset. The near-term investment and partnership case remains dominated by STM-01.

The broader platform may become more credible if STM-01 demonstrates that neonatal cardiac progenitor biology produces meaningful therapeutic effects in humans. Positive results could strengthen the rationale for isolating or engineering the factors responsible for those effects. Weak STM-01 results would not necessarily invalidate every secretome-based programme, but they would make investors and potential partners more demanding about mechanism, formulation and indication selection.

What should potential partners watch next from Secretome Therapeutics?

The next meaningful proof points will be clinical rather than organisational. Secretome Therapeutics must clarify the status, design and timelines of its Duchenne studies, including how the open-label THRIVE 2 programme connects with the planned pivotal development strategy. It must also provide interpretable human data from STM-01 studies and show that its manufacturing process can deliver consistent cellular potency at larger scale.

Regulatory feedback will be another important indicator. The company’s ability to define acceptable cardiac endpoints and a credible control strategy will determine whether its planned late-stage programme can support registration rather than merely generate encouraging exploratory findings.

Secretome Therapeutics has improved its capacity to address those challenges. The company now has dedicated leadership across clinical development, medical affairs, operations, finance and broader pipeline management, backed by fresh institutional capital. What remains unresolved is whether STM-01’s clinical evidence can develop as quickly as the organisation being built around it.

The leadership expansion should therefore be viewed as a preparedness milestone, not a therapeutic milestone. The decisive test will be whether Secretome Therapeutics can convert the scientific rationale behind neonatal cardiac progenitor cells into controlled, durable and clinically meaningful evidence in patients with Duchenne cardiomyopathy.

What are the key takeaways from Secretome Therapeutics’ rare disease leadership expansion?

• Secretome Therapeutics appointed Teji Singh as chief medical officer and added senior leaders across operations, medical affairs and finance.
• Former chief medical officer Marshelle Smith has transitioned to chief development officer to lead broader pipeline development.
• The appointments follow a $30 million Series A financing from RA Capital Management completed in May 2026.
• Secretome Therapeutics has disclosed at least $50.4 million across its November 2024 and May 2026 financing rounds.
• STM-01 is being developed as a neonatal cardiac progenitor cell therapy for Duchenne cardiomyopathy, dilated cardiomyopathy and heart failure with preserved ejection fraction.
• The leadership appointments add capabilities needed for late-stage trials, regulatory engagement, manufacturing, medical affairs and potential commercial preparation.
• The company’s proposed Duchenne study model includes home dosing and broad eligibility across age, ambulation and existing treatment status.
• Capricor Therapeutics’ deramiocel regulatory review could influence the evidence standards and competitive environment for STM-01.
• Secretome Therapeutics still needs controlled and durable clinical evidence showing that STM-01 improves or preserves meaningful cardiac outcomes.
• The next major test is whether the company’s expanding organisational readiness can be matched by clinical and regulatory progress.